Insight, China's Pharmaceutical Industry

Company Deals

Lepu’s Minwei Licenses MWN105 Injection to Denmark’s Sidera Bio, Up to $1.01 B in Milestones

Lepu (Beijing) Medical Technology Co., Ltd. (SHE: 300003) announced that its wholly‑owned subsidiary Shanghai Minwei...

Company Drug

Transcenta Holding Announces Positive Phase III Results for Inhibrx’s Ozekibart in Advanced Chondrosarcoma

Fineline Cube Oct 31, 2025

Transcenta Holding Limited (HKG: 6628) announced that its partner Inhibrx Biosciences, Inc. (NASDAQ: INBX) has...

Company Deals Drug

Boehringer Ingelheim Licenses Pre‑Clinical Small‑Molecule Program from Kyowa Kirin for Autoimmune Therapy

Fineline Cube Oct 31, 2025

Boehringer Ingelheim announced a licensing deal to acquire exclusive worldwide rights to a promising first‑in‑class...

Company Deals

Chengdu Maxvax Secures Series D Financing at Over RMB 400 Million to Accelerate Shingles and RSV Vaccine Development

Fineline Cube Oct 31, 2025

China‑based Chengdu Maxvax Biotechnology Co., Ltd. announced the successful completion of its Series D funding round,...

Company

BMS Reports Q3 2025 Results: 2% Global Revenue Growth

Fineline Cube Oct 31, 2025

US‑based Bristol-Myers Squibb (BMS; NYSE: BMY) delivered its third‑quarter 2025 earnings, showing a modest 2%...

Company

Gilead Sciences Reports 3% YoY Q3 2025 Revenue Growth, HIV Sales Up 4%

Fineline Cube Oct 31, 2025

Gilead Sciences Inc. (NASDAQ: GILD) today announced its third‑quarter 2025 financial results. Total revenues reached...

Company

MSD Reports 3% YoY Q3 2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio‑Pulmonary Portfolio

Fineline Cube Oct 31, 2025

Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) today announced its third‑quarter 2025 financial results,...

Company

Eli Lilly Reports 54% YoY Revenue Surge in Q3 2025, Raises Full‑Year Guidance to $63 B

Fineline Cube Oct 31, 2025

Eli Lilly & Co. (NYSE: LLY) today announced that its third‑quarter 2025 financial results exceeded...

Company Drug

Jebel Pharma Reports Positive Phase III Results for JJH201501 Antidepressant

Fineline Cube Oct 31, 2025

Jiangsu Jebel Pharma Co., Ltd. (SHA: 688566) today announced that its novel antidepressant JJH201501, developed...

Company Medical Device

Shanghai Bio‑Heart’s Iberis RDN System Gains UK MHRA Approval, Expands Global Commercial Reach

Fineline Cube Oct 31, 2025

Shanghai Bio‑Heart Biological Technology Co., Ltd. (HKG: 2185) announced that its subsidiary, Shanghai AngioCare Medical...

Company Drug

Transcenta Partner Inhibrx Reports Positive ChonDRAgon Results for Ozekibart, Plans FDA BLA Filing in 2026

Fineline Cube Oct 31, 2025

Transcenta Holding Limited (HKG: 6628) announced that its joint venture, Inhibrx Biosciences, Inc. (NASDAQ: INBX),...

Company Drug

HighTide Therapeutics Announces Positive Phase III Results for HTD1801 in Type 2 Diabetes

Fineline Cube Oct 31, 2025

HighTide Therapeutics, Inc. (HKG: 2511) today announced that its two Phase III clinical trials, SYMPHONY‑1 (NCT06350890)...

Others

Takeda Reports 3.9% YoY Revenue Decline in H1 2025, Citing Neuroscience Slump and FX Headwinds

Fineline Cube Oct 31, 2025

Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) released its first‑half 2025 financial results today,...

Company Deals

BrightGene Submits HKEX Prospectus, Aiming for Main‑Board Listing

Fineline Cube Oct 31, 2025

BrightGene Bio‑Medical Technology Co., Ltd. (SHA: 688166) filed its prospectus with the Stock Exchange of...

Company

Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib

Fineline Cube Oct 31, 2025

Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced its 2025 third‑quarter earnings today, reporting operating revenue...

Company Deals Drug

JW Therapeutics & Regeneron Sign Expanded TCR‑T Collaboration, Unlocking $50 Million in Funding

Fineline Cube Oct 31, 2025

JW Therapeutics Ltd. (HKG: 2126) announced today the signing of a supplementary strategic cooperation agreement...

Company Deals

Novo Nordisk Launches $9 Billion Unsolicited Bid for Metsera, Triggering Battle with Pfizer

Fineline Cube Oct 31, 2025

Novo Nordisk A/S (NYSE: NVO) announced today an unsolicited offer of USD 9 billion for Metsera, Inc....

Company Deals Medical Device

Thermo Fisher Secures $8.875B Clario Acquisition, Enhancing Digital‑Trial Endpoint Suite

Fineline Cube Oct 30, 2025

Thermo Fisher Scientific Inc. (NYSE: TMO) announced a definitive agreement to acquire Clario Holdings, Inc., a...

Company Deals

ModeX Therapeutics Locks $1 B+ Collaboration With Regeneron on Multispecific Antibody Technology

Fineline Cube Oct 30, 2025

ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK) announced a milestone license and collaboration...

Company Deals

Everest Medicines Secures Exclusive Rights to VIS‑101 in Greater China, Potential 2026 Phase 3 Launch

Fineline Cube Oct 30, 2025

Hong Kong‑listed Everest Medicines Limited (HKG: 1952) today announced a strategic agreement with Visara, Inc.,...

Insight, China's Pharmaceutical Industry

Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal

Kelun-Biotech Receives USD 89 Million Settlement Payment from Medilink Therapeutics Over ADC Pipeline Out-Licensing Dispute

HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies

Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline

QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug

Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC

Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria

Lepu’s Minwei Licenses MWN105 Injection to Denmark’s Sidera Bio, Up to $1.01 B in Milestones

Transcenta Holding Announces Positive Phase III Results for Inhibrx’s Ozekibart in Advanced Chondrosarcoma

Boehringer Ingelheim Licenses Pre‑Clinical Small‑Molecule Program from Kyowa Kirin for Autoimmune Therapy

Chengdu Maxvax Secures Series D Financing at Over RMB 400 Million to Accelerate Shingles and RSV Vaccine Development

BMS Reports Q3 2025 Results: 2% Global Revenue Growth

Gilead Sciences Reports 3% YoY Q3 2025 Revenue Growth, HIV Sales Up 4%

MSD Reports 3% YoY Q3 2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio‑Pulmonary Portfolio

Eli Lilly Reports 54% YoY Revenue Surge in Q3 2025, Raises Full‑Year Guidance to $63 B

Jebel Pharma Reports Positive Phase III Results for JJH201501 Antidepressant

Shanghai Bio‑Heart’s Iberis RDN System Gains UK MHRA Approval, Expands Global Commercial Reach

Transcenta Partner Inhibrx Reports Positive ChonDRAgon Results for Ozekibart, Plans FDA BLA Filing in 2026

HighTide Therapeutics Announces Positive Phase III Results for HTD1801 in Type 2 Diabetes

Takeda Reports 3.9% YoY Revenue Decline in H1 2025, Citing Neuroscience Slump and FX Headwinds

BrightGene Submits HKEX Prospectus, Aiming for Main‑Board Listing

Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib

JW Therapeutics & Regeneron Sign Expanded TCR‑T Collaboration, Unlocking $50 Million in Funding

Novo Nordisk Launches $9 Billion Unsolicited Bid for Metsera, Triggering Battle with Pfizer

Thermo Fisher Secures $8.875B Clario Acquisition, Enhancing Digital‑Trial Endpoint Suite

ModeX Therapeutics Locks $1 B+ Collaboration With Regeneron on Multispecific Antibody Technology

Everest Medicines Secures Exclusive Rights to VIS‑101 in Greater China, Potential 2026 Phase 3 Launch

You Missed

Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal

Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC

Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria

China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added